CLINICAL TRIALS PROFILE FOR CHLORPHENIRAMINE MALEATE

All Clinical Trials for Chlorpheniramine Maleate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00555542 ↗	An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis	Completed	Chinese University of Hong Kong	Phase 2	2006-07-01	To study the effects of T cell in peripheral blood of patients with RA undergoing selective B cell depletion have not been studied. We analyze the B and T cell subsets in patients with active RA treated undergoing this form of treatment with rituximab.
NCT00837837 ↗	Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 1	2008-12-21	The purpose of this study is to examine the pharmacokinetic parameters of chlorpheniramine in children and adolescents.
NCT01158326 ↗	Evaluation of Efficacy and Safety of Oral Solution Resfenol in Reducing Symptoms of Common Cold And Flu	Completed	Hospital de Clinicas de Porto Alegre	Phase 3	2010-08-01	This study aimed to evaluate the efficacy and safety of the oral solution of paracetamol, chlorpheniramine maleate and phenylephrine hydrochloride in reducing symptoms of flu and the common cold. There will be a randomized, double-blind, placebo-controlled trial. Will be included 216 subjects, male or female, aged greater than 12 and less than or equal to 60 years, irrespective of color and / or race with symptoms of recent onset, for more than 6 hours and less than 48 hours length, characterizing Common Cold and / or Influenza. After clinical evaluation and laboratory research subjects will be randomized to receive active drug or placebo, 10 ml oral solution every 6 hours for 48 hours. The follow-up visits will be held on 2 (24 hours after first intervention) and in 3 days (48 hours after first intervention). The outcomes to assess the effectiveness so far consist of the scores of symptoms and to assess the safety of the drug will be accompanied by the emergence of adverse events.
NCT01293201 ↗	Trial of STAHIST in Seasonal Allergic Rhinitis	Completed	Magna Pharmaceuticals, Inc.	Phase 3	2011-03-01	The overall development plan is to show that the combination of tried-and-proven decongestant/antihistamine ingredients (pseudoephedrine hydrochloride and chlorpheniramine maleate), plus a very small amount of belladonna alkaloids (.24 mg atropine sulfate) is a comprehensive, safe and effective B.I.D. drug treatment regimen, indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. Treated symptoms include nasal congestion, sneezing, rhinorrhea, itchy nose, itchy/watery eyes, and post nasal drip syndrome [reduction in tickly cough (acute or chronic), mucus in the back of the throat, sore throat, and hoarseness]. Considering the favorable safety and efficacy results of Phase 1 and Phase 2, the purpose of Phase 3 is to assess and compare the safety and efficacy of the study drug in a larger group comparatively with a placebo control group. Objectives: A) To report and compare total symptom scores (TSS) by SAR subjects rating the efficacy of STAHIST vs. placebo in relieving nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip over the two-week study period. B) Report any side effects or adverse drug reactions and rate the severity of any incident. C) Compare and report each symptom score, total nasal symptom scores (TNSS), and post-nasal drip symptom scores (PND-S) between the two study arms.

Clinical Trial Conditions for Chlorpheniramine Maleate

Condition Name

Condition Name for Chlorpheniramine Maleate
Intervention	Trials
Common Cold	2
Nasal Congestion	1
Nasal Congestion and Inflammations	1
Rheumatoid Arthritis	1

Condition MeSH

Condition MeSH for Chlorpheniramine Maleate
Intervention	Trials
Rhinitis	3
Common Cold	2
Rhinitis, Allergic	2
COVID-19	1

Clinical Trial Locations for Chlorpheniramine Maleate

Trials by Country

Trials by Country for Chlorpheniramine Maleate
Location	Trials
United States	8
China	2
Brazil	2
Honduras	1
Mauritius	1

Trials by US State

Trials by US State for Chlorpheniramine Maleate
Location	Trials
Florida	1
Texas	1
South Carolina	1
Ohio	1
Kentucky	1

Clinical Trial Progress for Chlorpheniramine Maleate

Clinical Trial Phase

Clinical Trial Phase for Chlorpheniramine Maleate
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	3
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for Chlorpheniramine Maleate
Clinical Trial Phase	Trials
Completed	7
Active, not recruiting	1
Terminated	1

Clinical Trial Sponsors for Chlorpheniramine Maleate

Sponsor Name

Sponsor Name for Chlorpheniramine Maleate
Sponsor	Trials
Sino-American Tianjin Smith Kline & French Laboratories Ltd	1
GlaxoSmithKline	1
Sephoris Pharmaceuticals LLC	1

Sponsor Type

Sponsor Type for Chlorpheniramine Maleate
Sponsor	Trials
Industry	6
Other	5

Clinical Trials Update, Market Analysis, and Projection for Chlorpheniramine Maleate

Last updated: January 27, 2026

Executive Summary

Chlorpheniramine Maleate, an antihistamine primarily utilized for allergic conditions, remains a significant pharmaceutical agent despite declining dominance in the allergy segment. Its patent status has largely expired, leading to widespread generic availability, but recent developments in clinical research and evolving market dynamics present opportunities and challenges. This report synthesizes recent clinical trial activity, analyzes current market trends, and projects future growth and diversification potentials for Chlorpheniramine Maleate.

---

Complexities in Clinical Development and Trials for Chlorpheniramine Maleate

What is the current landscape of clinical research involving Chlorpheniramine Maleate?

Key points:

• Research Focus: Predominantly on its efficacy for allergic rhinitis, urticaria, and allergic conjunctivitis.
• Recent Trials: A limited number of completed or ongoing trials mostly concentrate on combination therapies or alternative delivery methods.
• Trial Volume and Status:

Year	Number of Trials	Status	Primary Focus
2020	2	Completed, Published	Comparative efficacy with new antihistamines
2021	1	Recruiting	Use in pediatric allergic conditions
2022	0	No new registered studies
2023	1	Proposed, Pending Approval	Investigating novel delivery mechanisms

Sources: ClinicalTrials.gov databases (as of Q1 2023) indicate a stagnant clinical trial pipeline, reflective of mature drug status. The focus is predominantly on repurposing or combination formulations rather than new indications.

Are there ongoing innovations in delivery or formulation?

Yes. Several studies exploring:

• Extended-release formulations.
• Intranasal sprays.
• Combination with other antihistamines or corticosteroids.

However, these are primarily in early or preclinical stages, highlighting limited pipeline expansion.

How does the safety and efficacy profile influence ongoing research?

• Well-established safety profile—long history of OTC use.
• Comparative studies show comparable efficacy with modern antihistamines such as loratadine or cetirizine.
• Lack of novel mechanisms reduces incentives for extensive clinical research.

---

Market Analysis of Chlorpheniramine Maleate

What is the current market size and segmentation?

Global Market Valuation (2022): Estimated at approximately $180 million, with regional distributions as follows:

Region	Market Share	Key Drivers	Challenges
North America	40%	OTC availability, allergy prevalence, aging population	Stringent OTC regulations
Europe	30%	Prescription and OTC sales	Competition from newer antihistamines
Asia-Pacific	20%	Growing awareness, OTC access, population size	Regulatory hurdles, price sensitivities
Rest of World	10%	Emerging markets, local manufacturing	Supply chain, regulatory variability

Market Dynamics:

• Decline in Prescription Use: As newer antihistamines with fewer sedative effects dominate, Chlorpheniramine’s prescription segment shrinks.
• OTC Segment: Remains robust, especially in countries with less restrictive OTC policies.
• Generic Competition: High due to patent expiration (around 1957), multiple manufacturers globally.

Who are the key market players?

Company	Market Share	Focus Areas	Strategic Moves
Mylan (part of Viatris)	~15%	Generics, OTC formulations	Diversification into combination therapies
Sandoz (Novartis)	~10%	Multisource generics	Supply chain expansion
Teva Pharmaceuticals	~10%	Cost competitiveness	Focus on emerging markets

What are the regulatory considerations?

• OTC Classification: Predominant in many countries.
• Limited Prescriptive Use: Primarily for allergic conditions.
• Potential for New Indications: Regulatory agencies may require substantial evidence to expand uses, which is unlikely given current clinical data.

---

What are the future market projections?

Year	Estimated Market Size	Compound Annual Growth Rate (CAGR)	Primary Drivers	Risks
2023	$180 million	-	Steady OTC demand; minimal innovation	Market saturation; competition from new antihistamines
2025	$190 million	1.0%	Aging populations; OTC accessibility	Regulatory constraints; shifts in allergy treatment paradigms
2030	$200 million	0.8–1.0%	Potential niche applications; combination formulations	Patent challenges; decline in OTC effectiveness perception

Analysis: Growth is expected to be modest, primarily driven by existing OTC markets and demographic factors. The absence of significant pipeline innovation limits upside potential.

---

Comparative Overview of Chlorpheniramine Maleate and Modern Alternatives

Attribute	Chlorpheniramine Maleate	Cetirizine / Loratadine / Fexofenadine	Levocetirizine
Onset of Action	1–2 hours	1 hour	1 hour
Duration	4–6 hours	24 hours	24 hours
Sedative Effect	Moderate	Minimal	Minimal
Approval Status	OTC/Human use	OTC/Prescription	OTC
Patent Status	Expired	Expired	Patent expired / generic available
Clinical Evidence	Robust, historical use	Extensive, modern trials	Extensive, modern trials

Implication: Chlorpheniramine remains a cost-effective option with established efficacy but faces stiff competition from second-generation antihistamines with superior safety profiles and fewer sedative effects.

---

Key Regulatory and Policy Factors

• OTC Policy Variability: Regulatory landscape varies:

  • United States (FDA): OTC status widely accepted, with restrictions on labeling.
  • European Union (EMA): Similar OTC regulations but stricter marketing guidelines.
  • Emerging markets: Less restrictive, leading to wider use.

• Potential for New Indications: Limited, owing to maturity of existing clinical data.

• Repositioning Strategies: Focus on combination formulations or niche indications may benefit from regulatory pathways with expedited review processes.

---

Strategic Recommendations for Stakeholders

• Pharmaceutical Manufacturers:

  • Maintain inventory and supply chains given stable OTC demand.
  • Explore combination formulations with corticosteroids or decongestants.
  • Monitor emerging formulations such as intranasal or topical applications.

• Investors and Market Analysts:

  • Focus on mature OTC markets with steady demand.
  • Be cautious of obsolescence risks due to improved alternatives.
  • Track regulatory shifts and patent landscapes in key regions.

• Research & Development Entities:

  • Limited R&D investment justified primarily for niche or combination applications.
  • Investigate formulations that reduce sedative side effects or improve compliance.

---

Conclusion

Chlorpheniramine Maleate maintains a stable, albeit modest, global market primarily fueled by OTC sales. Clinical trial activity has plateaued, reflecting its status as a well-established agent. Market growth projections remain conservative, constrained by competition from newer antihistamines with superior safety profiles and limited pipeline innovation. Strategic focus should center on product differentiation via combination therapies, improved formulations, or niche applications.

---

Key Takeaways

• Market Stability: Chlorpheniramine Maleate benefits from established OTC demand, especially in emerging markets.
• Limited Innovation: Clinical trial activity is declining; no significant pipeline exists for new indications.
• Competitive Pressure: Second-generation antihistamines increasingly displace Chlorpheniramine in prescribed and OTC segments.
• Regulatory Environment: Varies regionally, influencing market access and promotional strategies.
• Future Outlook: Growth is expected to be minimal; opportunities exist predominantly for niche formulations or combination therapies.

---

FAQs

1. What are the main contraindications for Chlorpheniramine Maleate?
   Contraindications include hypersensitivity to pheniramine derivatives, use in narrow-angle glaucoma, urinary retention, and in elderly patients due to sedation risks.

2. Are there ongoing efforts to develop improved formulations of Chlorpheniramine?
   Current efforts focus on extended-release and intranasal delivery systems to enhance compliance and reduce sedative effects, mostly in early experimental stages.

3. Can Chlorpheniramine Maleate be combined with other medications?
   Yes, but combination products are mainly available for OTC markets; caution is advised due to potential interactions, especially with CNS depressants.

4. What regulatory hurdles exist for expanding Chlorpheniramine’s indications?
   Robust clinical trials demonstrating safety and efficacy are required; given existing data, agencies are unlikely to approve new indications without significant evidence.

5. How does the patent status impact the market?
   The patent expired in the late 20th century, leading to widespread generics and price competition, limiting the opportunity for branded innovation.

---

Sources:

[1] ClinicalTrials.gov, 2023.
[2] MarketsandMarkets. (2022). Global Antihistamine Market Reports.
[3] U.S. Food & Drug Administration. (2021). OTC Drug Review Findings.
[4] European Medicines Agency. (2022). Allergy and Respiratory Drugs Policy.
[5] Statista. (2022). OTC Drugs Market Size and Trends.